0000899243-21-035558.txt : 20210910 0000899243-21-035558.hdr.sgml : 20210910 20210910164709 ACCESSION NUMBER: 0000899243-21-035558 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210908 FILED AS OF DATE: 20210910 DATE AS OF CHANGE: 20210910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reeve Emma CENTRAL INDEX KEY: 0001680329 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 211247550 MAIL ADDRESS: STREET 1: C/O PAREXEL INTERNATIONAL CORPORATION STREET 2: 195 WEST STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-08 0 0001422142 Aadi Bioscience, Inc. AADI 0001680329 Reeve Emma C/O AADI BIOSCIENCE, INC. 17383 SUNSET BOULEVARD, SUITE A250 PACIFIC PALISADES CA 90272 1 0 0 0 Stock option (right to buy) 27.67 2021-09-08 4 A 0 16486 0.00 A 2031-09-08 Common Stock 16486 16486 D Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the Initial Award shall be fully vested on the three year anniversary of the grant date. The grant date is September 8, 2021. /s/ Lance Thibault, as Attorney-in-Fact 2021-09-10